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Fibroblast growth factor-21 (FGF21) signaling requires the presence of b-Klotho, a co-receptor with a
very short cytoplasmic domain. Here we show that FGF21 binds directly to b-Klotho through its C-
terminus. Serial C-terminal truncations of FGF21 weakened or even abrogated its interaction with
b-Klotho in a Biacore assay, and led to gradual loss of potency in a luciferase reporter assay but with
little effect on maximal response. In contrast, serial N-terminal truncations of FGF21 had no impact
on b-Klotho binding. Interestingly, several of them exhibited characteristics of partial agonists with
minimal effects on potency. These data demonstrate that the C-terminus of FGF21 is critical for
binding to b-Klotho and the N-terminus is critical for ﬁbroblast growth factor receptor (FGFR) acti-
vation.
Structured summary:
MINT-6799939: FGFR1c (uniprotkb:P11362) binds (MI:0407) to b-Klotho (uniprotkb: Q86Z14) by surface
plasmon resonance (MI:0107)
MINT-6799907, MINT-6799922: FGF21 (uniprotkb: Q9NSA1) binds (MI:0407) to b-Klotho (uni-
protkb: Q86Z14) by surface plasmon resonance (MI:0107)
 2008 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction co-receptor required for FGF/FGFR interactions (see review [8]Fibroblast growth factor-21 (FGF21) belongs to the FGF19 sub-
family, which consists of FGF19, 21 and 23 [1]. The FGF19 subfam-
ily members have emerged as potent endocrine hormones involved
in the regulation of diverse physiological homeostasis [2–4].
Administration of recombinant FGF21 lowered plasma glucose
and insulin levels, reduced hepatic and circulating triglycerides
and cholesterol levels, and improved insulin sensitivity, energy
expenditure, hepatic steatosis and obesity in a range of insulin
resistant animal models [4–6]. Hence, FGF21 has become an attrac-
tive therapeutic agent to treat human type 2 diabetes and the asso-
ciated metabolic syndrome.
Recent progress implied that functional differences between
FGF21 and traditional FGFs may arise from differences in their
receptor signaling components [7]. Traditional FGFs signal through
a family of high afﬁnity receptor tyrosine kinases (FGFR) in the
presence of heparin sulfate proteoglycan (HSPG), a low afﬁnitychemical Societies. Published by E
extracellular signal-regulatedand references therein). In contrast, the FGF19 subfamily requires
distinct Klotho transmembrane proteins as co-receptor for the acti-
vation of FGFR signaling [9]. a-Klotho is required for FGF23 to reg-
ulate renal phosphate metabolism [10], whereas b-Klotho is
required for FGF21 to regulate glucose and lipid metabolism [11]
and FGF19 to regulate bile acid metabolism [12] FGF21 is active
in adipocytes and pancreatic b-cells, which express both FGFRs
and b-Klotho [4,13,14]. Interestingly, when b-Klotho was transfec-
ted in non-responding ﬁbroblasts, FGF21-induced signaling was
observed [11,15]. In addition, immunoprecipitation studies indi-
cate that b-Klotho interacts with FGF21 and facilitates the forma-
tion of the FGF21–b-Klotho–FGFR ternary complex [11,15,16].
Moreover, siRNA knockdown of b-Klotho abolished FGF21-induced
signaling and its stimulatory effect on GLUT1 expression and glu-
cose uptake in 3T3-L1 adipocytes [16].
The FGFR isoforms mediating FGF21 signaling are not com-
pletely deﬁned. It is known that FGFR4 and the c-isoforms of
FGFR1, 2 and 3 are possible candidates [11,15–17]. Immunoprecip-
itation experiments showed that b-Klotho interacts with FGFR1c
and FGFR4 more efﬁciently than FGFR2c and 3c [11,15,16].
However, in the presence of b-Klotho, FGF21 could signal in BaF3
cells expressing either FGFR1c or 3c, but not 2c or FGFR4 [18]lsevier B.V. All rights reserved.
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[16]. Therefore, the c-isoforms of FGFRs rather than FGFR4 might
be physiologically relevant receptors for FGF21 and mediate
FGF21 activity through their respective tissue expression patterns.
Independently, FGFR4 has been shown to be a speciﬁc receptor for
FGF19 [19].
Despite the progress made in the identiﬁcation of FGF21 recep-
tor signaling components, the nature of the interactions between
FGF21, FGFR and b-Klotho is not completely understood. Struc-
ture-based modeling and sequence alignment suggest that FGF21
has a typical 120 aa b-trefoil core structure like the traditional
FGFs, but its N- and C-terminal sequences are signiﬁcantly differ-
ent from those of other FGFs ([9], and unpublished data). Here
we sought to use FGF21 N- and C-terminal truncations to identify
the regions of FGF21 responsible for FGFR and b-Klotho interac-
tions and thereby better understand these regions’ roles in FGF21
receptor activation.2. Materials and methods
2.1. FGF21, b-Klotho and FGFR1c protein and plasmids
Full-length and truncated human FGF21 proteins were
expressed in an Escherichia coli strain using a proprietary vector.
The expression was primarily found in inclusion bodies. The recov-
ery of oxidized proteins involved the dissolution of the inclusion
bodies and refolding of the soluble reduced protein. Brieﬂy, E. coli
cells were resuspended in water and lysed with a 110S Microﬂui-
dizer. The inclusion bodies were dissolved with a buffer of 8 M
guanidine, 50 mM Tris, pH 8.5, and 10 mM dithiothreitol. The
solution was subsequently added to a refolding solution to achieve
a ﬁnal concentration of 1 mg/ml. The refolded material was further
puriﬁed by anion exchange chromatography, followed by hydro-
phobic interaction chromatography. All deletion mutants were
tested by Western blotting and reverse-phase HPLC to ensure pro-
tein integrity. No deletion resulted in signiﬁcant structural changes
as judged by spectrum photometric measurement.
The extracellular domain of human b-Klotho (1–992) fused with
6xHis tag at the C-terminus was cloned into the pTT14 expression
vector. The extracellular domain of b-Klotho protein was puriﬁed
from a 293F stable cell line using Talon IMAC resin-Co2+ (Clontech)
according to the manufacturer’s protocol, and was further puriﬁed
with CHT Type I 40 lm column (Bio-Rad). The recombinant
FGFR1c-Fc fusion protein with the extracellular domain of FGFR1c
at the N-terminus was generated internally with similar method as
the protein available commercially from R&D systems.
2.2. ELK luciferase assay
ELK luciferase assay was performed in 293T cells that were sta-
bly transfected with human b-Klotho and reporter constructs con-
taining 5xUAS luciferase and GAL4 DNA-binding domain (DBD)
fused to ELK1. In this system, luciferase activity is regulated by
the endogenous phosphorylated extracellular signal-regulated ki-
nase (ERK). The 293T stable cells were seeded at 1  105 cells/well
on 96-well plates. On the next day, FGF21 proteins were added to
the media. The plates were incubated for 6 h. Cells were then lysed
to measure luciferase activity using the Bright-Glo luciferase assay
system (Promega).
2.3. Biacore binding studies
Binding of FGF21 and its mutants to human b-Klotho was tested
in a Biacore solution equilibrium binding assay. Brieﬂy, NeutrAvi-
din (Pierce) was immobilized on a CM5 chip using amine couplingreagents (GE Healthcare). Biotinylated FGF21 was captured on the
second ﬂow cell to 800RU. The biotinylated FGF21 has similar
activity as native FGF21 in the luciferase assay and the Biacore
binding assay (data not shown). Each FGF21 mutant was incubated
at three different concentrations (2 lM, 200 nM and 20 nM) with
10 nM human b-Klotho in a PBS buffer containing 0.1 mg/ml BSA
and 0.005% P20 for 1 h at room temperature. The pre-incubated
mixtures were injected over the biotin–FGF21 surface to measure
the binding of free b-Klotho. The signal obtained with no FGF21
mutant in the pre-incubation represents 100% b-Klotho binding
and serves as control. Decreased signal with increasing concentra-
tions of a given FGF21 mutant in the pre-incubation indicates that
it blocks b-Klotho binding to the immobilized biotin–FGF21 and
therefore, retains ability to bind to b-Klotho.
Binding of human b-Klotho to FGFR1c-Fc was also tested in the
Biacore assay. Brieﬂy, FGFR1c-Fc was immobilized on the second
ﬂow cell of a CM5 chip using amine coupling to 10000 RU. The
ﬁrst ﬂow cell was used as a background control. Twenty nanomo-
lars of human b-Klotho diluted in PBS plus 0.1 mg/ml BSA and
0.005% surfactant P20 was injected over the FGFR1c-Fc surface
for 5 min at 10 ll/min.
2.4. Statistical analysis
All data are means ± standard deviation (S.D.). Values were
compared using Student’s paired t-test. P < 0.05 was considered
as statistically signiﬁcant.3. Results
3.1. Direct interaction of FGF21 with b-Klotho
We developed a luciferase reporter assay system in 293T cells
that stably express human b-Klotho and reporter constructs. Then,
we measured and determined that these cells express multiple
FGFRs including FGFR1c endogenously (data not shown). When
FGF21was tested in this cell line, ERK phosphorylationwas induced
leading to elevated luciferase activity (EC50 = 0.5 nM, Fig. 1A). To
test whether FGF21 could directly bind to b-Klotho or FGFR, we
set up a competition assay using the same reporter system. FGFR1c
was selected as the FGFR since it is the most validated receptor for
the FGF21 signaling [11,15–17]. Either soluble b-Klotho alone or
FGFR1c-Fc alone did not affect luciferase activity (data not shown).
However, soluble b-Klotho decreased FGF21-induced luciferase
activity in a dose-dependent manner (IC50  110 nM, Fig. 1B), sug-
gesting that the soluble b-Klotho may directly bind to FGF21 and
sequester it from acting on the cells. In contrast, FGFR1c-Fc did
not inhibit FGF21 signaling (Fig. 1C), indicating that no interaction
between FGFR1c and FGF21 may have occurred. Interaction be-
tween b-Klotho and FGF21 was further assessed in a direct binding
study using Biacore. Interaction between FGF21 and b-Klotho was
detected (Fig. 1D). Soluble FGF21 inhibited b-Klotho binding to
immobilized FGF21 with an IC50 around 18.6 nM (Fig. 1D). The esti-
mated Kd (koff/kon) value is approximately 15 nM. No direct binding
between FGFR1c and FGF21was detected (data not shown), a result
that is consistent with the ﬁnding from the luciferase assay where
soluble FGFR1c did not inhibit FGF21 signaling (Fig. 1B). Other
FGFRs such as FGFR2c, FGFR3c and FGFR4 were also tested in the
Biacore assay and no direct binding between these FGFRs and
FGF21 was detected (data not shown).
3.2. Synergism of FGFR1c and b-Klotho in FGF21 signaling
Several immunoprecipitation experiments have shown that b-
Klotho interacts with FGFR1c [11,15,16]. Surprisingly, b-Klotho/
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Fig. 1. Interaction of FGF21 with b-Klotho. (A) FGF21 stimulates luciferase activity in a dose-dependent manner as measured in a 293T reporter cell line stably expressing
human b-Klotho and reporter genes (EC50  0.5 nM). (B) Soluble b-Klotho inhibits FGF21 activity in the same reporter assay. Different amounts of soluble b-Klotho were
incubated with EC90 amount of FGF21 (5 nM) for 15 min on ice before being added to the cells. The IC50 for b-Klotho inhibition is 110 nM. (C) Different amounts of soluble
FGFR1c-Fc were incubated with 5 nM FGF21 before being added to the cells. Soluble FGFR1c-Fc did not inhibit FGF21 activity in the reporter assay. (D) FGF21 directly binds to
b-Klotho in a Biacore assay. Shown is the binding sensorgram of b-Klotho to immobilized biotin–FGF21. Biotin–FGF21 was captured on a CM5 chip coated with NeutrAvidin.
Human b-Klotho (10 nM) was pre-incubated with different amounts of FGF21 for 1 h before the mixture was injected over the biotin–FGF21 surface. b-Klotho bound to the
chip surface was quantitated. (E) FGFR1c-Fc directly binds to b-Klotho in a Biacore assay. Shown is the binding sensorgram of 20 nM b-Klotho to immobilized FGFR1c-Fc. (F)
Synergism between soluble FGFR1c-Fc and soluble b-Klotho in inhibiting FGF21 from activation was observed in the reporter assay. FGF21 (5 nM), soluble b-Klotho (125 nM),
and soluble FGFR1c-Fc (500 nM) were pre-incubated for 15 min before being added to the cells. The inhibition by the mixture of FGFR1c-Fc and b-Klotho was signiﬁcantly
greater than b-Klotho alone (P < 0.05 compared with b-Klotho alone).
J. Yie et al. / FEBS Letters 583 (2009) 19–24 21FGFR1c interaction was remarkably weak in our Biacore assay
(Fig. 1E). We estimated that the Kd for b-Klotho/FGFR1c interaction
was greater than 100 nM.
Since both b-Klotho and FGFR1c are required for FGF21 activity,
we next tried to determine if both receptors could bind to FGF21
cooperatively. A suboptimal dose of soluble b-Klotho (125 nM),
which could only partially inhibit FGF21 activity (Fig. 1F), was
pre-incubated with FGFR1c and FGF21. The mixture was then
added to the cells. Interestingly, when FGFR1c and b-Klotho were
added together, FGF21 activity was suppressed to a greater degree
than b-Klotho alone (Fig. 1F). This effect appeared to be synergistic
and was seen in the presence of a broad range of b-Klotho concen-
trations (data not shown). Thus, b-Klotho and FGFR1c may form a
complex with a higher afﬁnity for FGF21 than b-Klotho alone. In
contrast, the synergistic effect of b-Klotho/FGFR1c was not seen
in a similar experiment when soluble FGFR4 and b-Klotho were
added together (data not shown).3.3. FGF21 binds to b-Klotho through its C-terminal region and the
interaction regulates FGF21 potency
In order to identify the regions of FGF21 that interact with its
receptors, we generated a series of FGF21 deletion mutants. We
ﬁrst focused on the C-terminus as this region of FGF23, a close fam-
ily member of FGF21, is critical for the interaction with a-Klotho
[9]. As shown in Fig. 2B, serial C-terminal deletions of FGF21 re-
sulted in gradual loss of its binding to b-Klotho, and 14 aa deletion
at the C-terminus resulted in complete loss of b-Klotho binding.
Interestingly, serial C-terminal deletions of FGF21 also resulted in
gradual loss in potency when tested in the reporter assay
(Fig. 2C), and the reporter activity was completely lost when the
C-terminal 14 aa were removed (Fig. 2C). Despite the loss of po-
tency, it appears that most C-terminal deletion mutants main-
tained full efﬁcacy (maximal response) (Fig. 2C). The afﬁnity of
FGF21 C-terminal deletion mutants for b-Klotho matched the po-
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Fig. 2. C-terminal FGF21 is critical for b-Klotho binding and the binding to b-Klotho determines FGF21’s potency in the reporter assay. (A). Shown is the amino acid sequence
of human FGF21. Signal peptide sequence is omitted. Underlined is the predicted b-trefoil core domain of FGF21 [9]. (B) Biacore data with FGF21 C-terminal deletion mutants.
As described in Fig. 1D, different amounts of FGF21 deletion mutants were incubated with 10 nM b-Klotho for 1 h before the mixture was injected over the biotin–FGF21
surface. Free b-Klotho was used as a control to demonstrate maximal binding. Concentrations of FGF21 constructs used are: white bar, 2 lM; gray bar, 200 nM; black bar,
20 nM. (C) The luciferase reporter assay of the selected FGF21 C-terminal deletion mutants in the 293T stable cell line. These data have been repeated multiple times with
triplicate in each experiment.
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chor that brings FGF21 to the close proximity of FGFR to induce re-
porter-mediated signaling.3.4. The N-terminal region of FGF21 is important for FGF21 activation
To understand the role of N-terminal FGF21 in receptor interac-
tion, we generated N-terminal serial deletion mutants of FGF21. In
contrast to the C-terminal deletions, all the N-terminal deletion
mutants of FGF21 retained their binding to b-Klotho in the Biacore
assay (Fig. 3A). In the reporter assay, a slight increase in efﬁcacy
was observed when the ﬁrst 4 aa were removed at the N-terminus,
suggesting that these 4 aa are not required for FGF21 activity
(Fig. 3B). When additional N-terminal amino acids were deleted,
gradual decreases in efﬁcacy (maximal response) were noticed
(Fig. 3B). FGF21 signaling was almost completely lost after removal
of 8 aa at the N-terminus (9–181, Fig. 3B). Interestingly, all N-ter-
minal deletions had very little effect on potency (EC50) (Fig. 3B).
The reporter activation curves for the N-terminal deletion mu-
tants exhibited partial agonist characteristics (Fig. 3B). To further
demonstrate partial agonist properties of these mutants, we as-
sessed the effect of different concentrations of 7–181 on the repor-
ter activity in the presence of full-length FGF21 at 5 nM
concentration (EC90 dose). Interestingly, 7–181 inhibited the
full-length FGF21 signaling in a dose-dependent manner, with
the maximal inhibitory response corresponding to the maximalactivation obtained with 7–181 alone (Fig. 3C). These data con-
ﬁrmed the notion that 7–181 is a partial agonist as it can inhibit
the activity by the full agonist. Also, it is fair to assume that the
partial agonist effect was not caused by changes in b-Klotho bind-
ing since the N-terminal deletion mutants retained their ability to
bind to b-Klotho (Fig. 3A). In contrast to the N-terminal deletion
mutants, the C-terminal deletion mutant 1–171 did not suppress
FGF21 signaling (Fig. 3D), suggesting that these mutants are simply
weak agonists. Interestingly, most C-terminal deletion mutants
acted as full agonists despite their reduced potency and binding
to b-Klotho ( Fig. 2B and C). Altogether, these data suggest that
the N- and C-termini of FGF21 likely play very different roles in
b-Klotho binding and FGFR activation.4. Discussion
FGF21, along with FGF19 and FGF23, belongs to an unusual sub-
family of the FGF superfamily. Traditional FGFs have no co-recep-
tors, and they directly induce FGFR dimerization, a common
activation mechanism for most FGFs [20]. However, the FGF19 sub-
family members require the Klotho proteins as co-receptors in
receptor activation. FGF21 signaling requires b-Klotho, which has
only a few amino acids in the intracellular region [14]. Hence,
FGF21 signaling seems to be solely conducted through FGFR.
How FGF21 interacts with FGFR or b-Klotho is not clear. In this pa-
per, we showed that the FGF21 C-terminus is critical for b-Klotho
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Fig. 3. N-terminal FGF21 deletions resulted in partial agonist effect and have no impact on b-Klotho interaction. (A) The N-terminal deletion mutants were assessed for their
ability to block b-Klotho binding to FGF21. Experimental procedure is same as described in Figs. 1D and 2A. Concentrations of FGF21 constructs used were: white bar, 2 lM;
gray bar, 200 nM; black bar, 20 nM. (B) The luciferase reporter assay of the selected FGF21 N-terminal deletion mutants in the 293T stable cell line. These data have been
repeated multiple times with triplicate in each experiment. The EC50 data shown are the average data of multiple experiments. 8–181 and 9–181 have been repeated at higher
doses to obtain more accurate EC50 value. (C) 7-181 inhibited the activity of full-length FGF21 in the reporter assay. 7–181 was pre-incubated with 5 nM full-length FGF21 for
15 min at room temperature before added to the 293T stable cells for reporter assay. (D) 1–171 did not compete with full-length FGF21 in the reporter assay.
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Deleting the C-terminus resulted in loss of potency in the luciferase
assay, whereas deleting the N-terminus led to reduced maximal re-
sponse, or partial agonist effect.
Structure modeling suggests that FGF21 has a typical 120 aa b-
trefoil core structure as seen in the traditional FGFs, but its N- and
C-terminal sequences are signiﬁcantly different from those in other
FGFs [9]. Our study demonstrated that the 14 aa at C-terminus
were necessary for b-Klotho binding and overall FGF21 activity.
The relative importance of the individual amino acids in b-Klotho
binding could be determined using alanine-scanning in the future.
Further, C-terminal deletions reduced the afﬁnity for b-Klotho and
the potency in the reporter assay, suggesting that b-Klotho binding
is critical to obtain FGF21 potency. Interestingly, a naturally occur-
ring form of FGF23 that lacks the C-terminal 73 aa [21] failed to
bind to a-Klotho and was inactive in signaling [9]. This ﬁnding is
consistent with our data with the FGF21 C-terminus and together
they suggest that the C-terminus of the FGF19 subfamily members
may be critical for co-receptor binding. Also, our data further imply
that b-Klotho binding may be a prerequisite for FGF21 activation.
Unlike traditional FGFs, FGF21 acts independently of heparin [9].
This allows FGF21 to escape cell membranes which are abundant
with HSPG and function as an endocrine factor [9]. Our data is con-
sistent with the endocrine nature of FGF21 in using b-Klotho as an
anchor to avoid misﬁring. It is the combination of tissue-speciﬁc
expression of b-Klotho and FGFR subtypes that deﬁne tissue selec-
tivity of FGF21 [16].
In contrast, the N-terminus of FGF21 does not play a role in b-
Klotho binding. The N-terminal deletions of FGF21 retained bind-
ing to b-Klotho in the Biacore assay, and had very little impact
on FGF21 potency in the luciferase assay. Instead, decreases in efﬁ-
cacy (maximal response) were observed with these mutants. Fur-
thermore, the efﬁcacy was drastically reduced with 6 aa deletion
at the N-terminus and completely lost with 8 aa deletion. This de-
creased efﬁcacy suggests that these deletion mutants behave aspartial agonists. Indeed, in the reporter activation assay, 7–181
inhibited the activity of the full-length FGF21, a typical character-
istic of a partial agonist. Although the N-terminus of FGF21 is
important for efﬁcacy, it is not clear what role this region plays
in FGFR activation. One study on FGF1–FGFR3c structure revealed
extensive interactions between the bC0–bE loop (within the D2 do-
main of FGFR3c) and the N-terminal region of FGF1 [22], under-
scoring the importance of the N-terminal region in conferring
receptor binding afﬁnity and promiscuity. However, to date, no
evidence of direct interaction between FGF21 and FGFR has been
reported. We were not able to demonstrate direct interaction be-
tween FGF21 and FGFR1c in the Biacore assay (data not shown).
Modeling studies suggest that the FGF19 subfamily members
may have inherently low afﬁnity for their FGFRs [9]. The potential
participation of FGF21 N-terminus in receptor interaction and acti-
vation will require further investigation.
While this manuscript was prepared, a different group showed
similar data on FGF21 N- and C-termini deletion mutants [23]. It
conﬁrmed our ﬁndings of the role of the C-termini in b-Klotho
binding. However, this group did not identify the partial agonist ef-
fect of N-terminal deletion mutants, probably due to relatively low
sensitivity of the assays in their study.
Our data suggest that b-Klotho may play a central role by bind-
ing to and recruiting FGF21 to FGFR to induce activation. When sol-
uble FGFR1c and b-Klotho were incubated with FGF21, they
exhibited greater inhibitory effect on FGF21 activity than b-Klotho
alone (Fig. 1E). Even though speciﬁc interaction between FGFR1c
and b-Klotho has been detected in immunoprecipitation experi-
ments [11,15,16], the binding afﬁnity of FGFR1c for b-Klotho is
low (Kd > 100 nM, Fig. 1E). In addition, the relative binding afﬁnity
of FGF21 for b-Klotho is also weak (Kd  15 nM, Fig. 1D). Given the
high potency of FGF21 in the reporter activation assay
(EC50  0.5 nM) and the data mentioned above, FGF21, b-Klotho
and FGFR1c may form a ternary complex in a highly coordinated
manner.
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